Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review.
BACKGROUND
An association between the bacterium Staphylococcus aureus and atopic eczema has been recognized for many years. Although few would dispute the benefit of systemic antibiotics in people with overtly clinically infected eczema, the clinical role of S. aureus in causing inflammatory flares in clinically uninfected eczema is less clear.


OBJECTIVE
To see if atopic eczema can be improved by antistaphylococcal agents, we performed a systematic review of randomized controlled trials (RCTs) using Cochrane Skin Group's Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE (from 2000), EMBASE (from 1980), the metaRegister of Current Controlled Trials (to March 2009), plus manual searching of references and conference proceedings. RCTs that compared interventions to reduce S. aureus in people with atopic eczema with no treatment, vehicle, or another active compound were included. Publication status and language were not barriers to inclusion.


RESULTS
Twenty-six studies involving 1229 participants were included. The studies were generally short term and of poor quality. There was no significant difference in global outcome for clinically infected eczema when oral antibiotics were compared with placebo [one study, relative risk (RR) 0.40, 95% confidence interval (CI) 0.13-1.24] or when topical steroid antibiotic combinations were compared with steroid alone (two studies, RR 0.52, 95% CI 0.23-1.16). One study of children with infected eczema that added bleach to bathwater showed a significant improvement in eczema severity when compared with bathwater alone, although the difference could have been explained by regression to the mean. Although antistaphylococcal interventions reduced S. aureus numbers in people with clinically uninfected eczema, none of the studies showed any clinical benefit.


CONCLUSIONS
We failed to find any evidence that commonly used antistaphylococcal interventions are clinically helpful in people with eczema that is not clinically infected. Their continued use should be questioned in such situations, until better and longer-term studies show clear evidence of clinical benefit.
Bath-Hextall
F J
FJ
Centre of Evidence-based Dermatology, Faculty of Medicine and Health Science, University of Nottingham, Nottingham, UK. Fiona.bath-Hextall@nottingham.ac.uk
Birnie
A J
AJ
Ravenscroft
J C
JC
Williams
H C
HC
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003020:Clothing; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018030:Silver Compounds / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000302:isolation & purification*; D013256:Steroids / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D018030:Silver Compounds; D013256:Steroids